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Single-inhaler triple therapy in patients
with chronic obstructive pulmonary
disease: a systematic review
Sue Langham1* , Jen Lewis1, Nick Pooley1, Nina Embleton1, Julia Langham1, MeiLan K. Han2 and
James D. Chalmers3
Abstract
Background: Guidelines recommend that treatment with a long-acting β2 agonist (LABA), a long-acting muscarinic
antagonist (LAMA), and inhaled corticosteroids (ICS), i.e. triple therapy, is reserved for a select group of symptomatic
patients with chronic obstructive pulmonary disease (COPD) who continue to exacerbate despite treatment with
dual therapy (LABA/LAMA). A number of single-inhaler triple therapies are now available and important clinical
questions remain over their role in the patient pathway. We compared the efficacy and safety of single-inhaler
triple therapy to assess the magnitude of benefit and to identify patients with the best risk-benefit profile for
treatment. We also evaluated and compared study designs and population characteristics to assess the strength of
the evidence base.
Methods: We conducted a systematic search, from inception to December 2018, of randomised controlled trials
(RCTs) of single-inhaler triple therapy in patients with COPD. The primary outcome was the annual rate of moderate
and severe exacerbations.
Results: We identified 523 records, of which 15 reports/abstracts from six RCTs were included. Triple therapy
resulted in the reduction of the annual rate of moderate or severe exacerbations in the range of 15–52% compared
with LAMA/LABA, 15–35% compared to LABA/ICS and 20% compared to LAMA. The patient-based number needed
to treat for the moderate or severe exacerbation outcome ranged between approximately 25–50 (preventing one
patient from having an event) and the event-based number needed to treat of around 3–11 (preventing one
event). The absolute benefit appeared to be greater in patients with higher eosinophil counts or historical
frequency of exacerbations and ex-smokers. In the largest study, there was a significantly higher incidence of
pneumonia in the triple therapy arm. There were important differences in study designs and populations impacting
the interpretation of the results and indicating there would be significant heterogeneity in cross-trial comparisons.
Conclusion: The decision to prescribe triple therapy should consider patient phenotype, magnitude of benefit and
increased risk of adverse events. Future research on specific patient phenotype thresholds that can support
treatment and funding decisions is now required from well-designed, robust, clinical trials.
Trial registration: PROSPERO #CRD42018102125.
Keywords: Chronic obstructive pulmonary disease, Inhalers, Combination drug therapy, Disease exacerbation
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Background
Chronic obstructive pulmonary disease (COPD) is a
leading cause of mortality and morbidity worldwide [1].
Pharmacological treatment relies predominately on in-
haled bronchodilators and anti-inflammatory agents [2].
The 2019 Global Initiative for Chronic Obstructive Lung
Disease (GOLD) strategy document, based on the best-
available evidence from the published literature, recom-
mend that choice of treatment depends on symptom
and exacerbation severity. In those patients with a high
risk of exacerbations, therapy relies on a long-acting
muscarinic antagonist (LAMA) or if a patient is highly
symptomatic, dual therapy with a LAMA and a long-
acting β2 agonist (LABA). Evidence suggests that dual
therapy with LABA and inhaled corticosteroids (ICS)
and the step up to triple therapy (LAMA/LABA/ICS) be
considered for a select group of patients who continue
to exacerbate despite appropriate treatment and/or fea-
tures suggesting steroid responsiveness.
Triple therapy, provided as multiple inhalers, has in
pooled analyses been shown to improve lung function,
health-related quality of life and exacerbations [3–7].
However, evidence suggests that triple therapy is often
over prescribed in clinical practice and used in patients
who are not frequent exacerbators [8–10]. Recently, two
single-inhaler triple therapies have received marketing
authorisation from the European Medicines Agency and
one other is in late-stage clinical development [11]. A
systematic and critical review of the evidence base for
single-inhaler triple therapy is warranted to support clin-
ical decision making for the following reasons. First, im-
portant questions in clinical practice remain over the
role of triple therapy, which include the magnitude of
clinical benefit and the identification of patients with the
best risk-benefit profile for treatment. Second, the ran-
domised controlled trial data for single-inhaler therapies
will be used to inform the evidence base for triple ther-
apy as a whole, therefore it is important to understand
its strengths and limitations. To the best of our know-
ledge there are currently no systematic reviews that give
a comprehensive and critical assessment of the evidence
base for single-inhaler triple therapy.
Following the GOLD 2019 update, such a review
would provide insights into patients most suited to triple
therapy, the strength of the evidence base and the need
for future research. The main objective of this study was
to conduct a systematic review of randomised controlled
trials comparing the efficacy and safety of fixed-dose
combinations of a LABA, LAMA and ICS (single-inhaler
triple therapy) with LABA, LAMA, LABA/LAMA or
LABA/ICS for the treatment of adult patients with
COPD. We present the relative and absolute benefit of
single-inhaler triple therapy overall and for specific pa-
tient subgroups for each trial. We also present estimates
of number needed to treat (NNT) and an overview of
risks associated with treatment to support clinical deci-
sion making. In addition, we present and discuss the
characteristics of each trial, highlighting how study de-
sign features could impact the interpretation of clinical
trial results and cross-trial comparisons.
Methods
We followed the Preferred Reporting Items for System-
atic Reviews and Meta Analyses (PRISMA) guidelines
for conducting and reporting systematic reviews [12].
The study protocol was prepared and published via
PROSPERO (#CRD42018102125) [13]. Eligibility criteria
included (see Additional file 1: Table S1): population of
adult patients with COPD; intervention of single-inhaler
triple therapy; comparators of LABA, LAMA, LAMA/
LABA or LABA/ICS; and study design of parallel-group
randomised controlled trials of ≥3 months duration.
Single-inhaler triple therapies of interest included glyco-
pyrronium bromide/formoterol fumarate/beclomethasone
(GLY/FOR/BDP; Trimbow®), umeclidinium/vilanterol/flu-
ticasone furoate (UMEC/VI/FF; Trelegy Ellipta), GLY/
FOR/budesonide (GLY/FOR/B; PT010) and GLY/indaca-
terol/mometasone furoate (GLY/IND/MF; QVM149). The
primary outcome of interest was the annual rate of mod-
erate and severe exacerbations. Moderate exacerbations
were those that required treatment with systemic cortico-
steroids and/or antibiotics. Severe exacerbations were
those that required hospitalisation or resulted in death
[14]. Secondary outcomes included time to first exacerba-
tion, lung function, quality of life and safety outcomes
(including serious adverse events [SAEs], pneumonia
and mortality).
Searches for full-text reports and conference abstracts
containing original data (in English) were run in: MED-
LINE, EMBASE, Cochrane Central Register of Con-
trolled Trials, ClinicalTrials.gov and the World Health
Organization International Clinical Trial Registry Plat-
form. The final update was in December 2018. The de-
tailed search strategy is available in Additional file 1:
Table S2.
Two reviewers (SL and JLe) independently screened
the titles and abstracts of citations, and then full-text re-
ports/conference abstracts according to the protocol.
Those studies, containing original data, which met the
eligibility criteria of this review were included. Disagree-
ments were resolved through consensus or consultation
with a third reviewer (JLa or NP). Data were extracted
by one author (JLe) and checked independently by two
reviewers (SL and NP). Disagreement between the au-
thors was solved by consensus or involvement of a
fourth reviewer (JLa). For the primary outcome we ex-
tracted data for the overall population and for several
phenotypic subgroups including prior exacerbation
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frequency, blood eosinophil levels/counts and smoking
status.
The risk of bias was assessed according to recommen-
dations outlined in the Cochrane Handbook for System-
atic Reviews of Interventions, and graded [15]. The tool
includes an assessment of sequence generation, conceal-
ment of allocation, blinding of participants and investi-
gators, incomplete outcome data and selective outcome
reporting. Each source of bias was graded as having high,
low or unclear risk.
Data assimilation on the primary and secondary out-
comes was through descriptive analysis in the form of
tables, figures and descriptive forest plots. Rate ratios
(RRs) for the comparison of the annual rate of moderate
and severe exacerbations between triple therapy and
comparators were displayed, for each study separately,
on a forest plot for the overall trial population and for
phenotypic subgroups. Where RR and 95% confidence
intervals (CIs) were not available from each study they
were calculated from the rate of annual moderate or se-
vere exacerbation for triple therapy and comparators
and the number of patients per subgroup using the RR
in ‘R’ version 3.3.2. Where RR were available from each
study, but 95% CIs were graphically displayed, we ap-
proximated the CIs from the forest plots reported in the
original publication using graphical software (GetData
Graph Digitizer).
We also calculated patient- and event-based NNT
for the primary outcome for each of the 12-month
studies. Patient-based NNT demonstrates the number
of patients that need to be treated with triple therapy
relative to the comparator to prevent one patient
from having ≥1 moderate or severe exacerbation over
one year. As the proportion of patients with ≥1 ex-
acerbation was rarely reported, proportions were ap-
proximated from the Kaplan–Meier curves for the
time to the first exacerbation using graphical software
(GetData Graph Digitizer). Event-based NNT demon-
strates the number of patients that need to be treated
to prevent one moderate or severe exacerbation.
These were calculated based on the annual rate of
moderate or severe exacerbations.
Results
The initial search returned 523 references after de-
duplication. From these, we identified 105 as potentially
relevant. A full-text analysis led to the removal of 90,
leaving 15 records (seven abstracts/posters) belonging to
six studies for inclusion (Fig. 1) [16–30]. Detailed rea-
sons for exclusion are outlined in Additional file 1: Table
S3. The majority of studies were excluded because they
reported results for interventions or comparators not in-
cluded in the eligibility criteria.
The characteristics of the included studies are dis-
played in Table 1. The six studies included in this review
had enrolled 19,658 participants with COPD (range 1810
to 10,355). All of the included studies were multi-
national, randomised, double-blind, parallel-group trials.
Four of the six studies were 1-year duration (TRINITY
[16], TRILOGY [17], TRIBUTE [23] and InforMing the
PAthway of COPD Treatment [IMPACT] [25]). The pri-
mary endpoint in one study was assessed after 24 weeks,
but a subset of patients continued treatment for ≤1 year
(Lung FUnction and quality of LiFe assessment in COPD
with closed triple therapy [FULFIL] [24]). The final study
was 24-weeks duration (KRONOS [26]).
Fig. 1 Flow chart of search results
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The mean age of participants in the different studies
was relatively similar (63.3–65.9 years). All the studies
had more male than female participants (66–77% males).
Where reported, the duration of COPD was similar be-
tween five of studies (7.7–8.2 years); the duration of
COPD in the KRONOS study was slightly lower (5.4–
6.2 years).
Disease-specific study characteristics are outlined in
Table 1. Participants’ post-bronchodilator forced expira-
tory volume in one second (FEV1) was 36% of predicted
normal value in three of the studies (TRINITY, TRIL-
OGY and TRIBUTE), and 45–47% in two of the studies
(FULFIL and IMPACT); the percentage predicted post-
bronchodilator FEV1 was not reported in the KRONOS
study. In terms of symptoms, patients from all the stud-
ies were required to have a baseline COPD assessment
test (CAT) score of ≥ 10 (CAT scores range from 0 to
40). The baseline CAT score was 20–21 in the TRIN-
ITY, TRILOGY, TRIBUTE and IMPACT studies; and
18–19 in the KRONOS study (the FULFIL study did not
report a mean baseline CAT score).
Patients from all studies, except the FULFIL and KRO-
NOS studies, were required to have had ≥ 1 exacerba-
tion in the previous year. Patients enrolled into the
TRINITY, TRILOGY and TRIBUTE studies all had ≥ 1
moderate or severe exacerbation in the previous 12
months. The FULFIL study inclusion criteria were either
FEV1 < 50% predicted or ≥ 2 moderate or ≥ 1 severe ex-
acerbation with FEV1 50–80% predicted; and the IM-
PACT study inclusion criteria were either ≥ 1 moderate
or severe exacerbation with FEV1 < 50% predicted, or ≥ 2
moderate or ≥ 1 severe exacerbation(s) with FEV1 50–
80% predicted. Patients in the KRONOS study were not
required to have had a COPD exacerbation within the
previous year. Exacerbation rate was a primary objective
for the TRINITY, TRIBUTE and IMPACT studies and a
secondary objective for the TRILOGY, FULFIL and
KRONOS studies (lung function was the primary end-
point for these studies).
Three of the studies (TRINITY, TRILOGY and TRIB-
UTE) excluded patients who were already on triple ther-
apy and did not permit other COPD treatments during
the trial; however, 64–78% of patients had received ICS-
containing regimens prior to the study start. The FUL-
FIL and IMPACT studies included patients who were
already on triple therapy and allowed patients to take
their existing medications during the run-in period.
Around 32–40% of patients were receiving triple therapy
during the run-in period and 66–72% of patients were
receiving a regimen that included an ICS. In the KRO-
NOS study, 23–32% of patients had previously taken
triple therapy, and were not permitted to take LAMA,
LABA, LAMA/LABA or LABA/ICS during the trial; 71–
73% of patients were receiving ICS at screening.
All of the studies excluded patients with a current
diagnosis of asthma. Patients with a prior history of
asthma were eligible to enrol in the IMPACT study if
they had a current diagnosis of COPD.
The studies generally had a low risk of bias according
to the Cochrane risk of bias tool [15] (see Additional file
1: Figure S1). There was an unclear risk of bias for selec-
tion (allocation concealment), performance bias (blind-
ing of participants and personnel) and detection bias
(blinding of outcome assessment) in the FULFIL study
due to insufficient information. For the IMPACT study,
there was an unclear risk of detection bias (blinding of
outcome assessment) also due to insufficient informa-
tion. The TRINITY, TRILOGY and TRIBUTE studies
were funded by Chiesi Farmaceutici, the FULFIL and
IMPACT studies were funded by GlaxoSmithKline, and
the KRONOS study was funded by Pearl Therapeutics –
a member of the AstraZeneca Group.
Primary outcome
The rate of moderate or severe exacerbations during
treatment among patients assigned to each intervention
is outlined in Fig. 2. The rates were much higher in the
IMPACT study and the LAMA/LABA group in the
KRONOS study compared with the other studies.
Figure 3 outlines the RR, 95% CIs and patient- and
event-based NNTs for triple therapy compared with
each comparator for each study for the overall popula-
tion and each subgroup for the primary outcome. The
graph is a descriptive display of the data for each study.
Overall population
For overall populations, the rate of moderate or severe
exacerbations was generally significantly lower for triple
therapy than the comparators. In the studies that
assessed single-inhaler triple therapy with a LAMA/
LABA (GLY/FOR/BDP versus GLY/IND; UMEC/VI/FF
versus UMEC/VI; and GLY/FOR/B versus GLY/FOR),
triple therapy resulted in RR of: 0.85 (95% CI: 0.72,
0.995; 15% difference; p = 0.043) [23]; 0.75 (95% CI: 0.70,
0.81; 25% difference; p < 0.001) [25]; and 0.48 (95% CI:
0.37, 0.64; 52% difference; p < 0.0001) [26]. The patient-
based NNT with triple therapy compared with LAMA/
LABA ranged between approximately 33 (IMPACT) and
50 (TRIBUTE). The event-based NNT ranged from 3
(IMPACT) to 11 (TRIBUTE).
In the studies that assessed single-inhaler triple therapy
with a LABA/ICS (GLY/FOR/BDP versus FOR/BDP;
UMEC/VI/FF versus VI/FF; UMEC/VI/FF versus FOR/B;
GLY/FOR/B versus FOR/B), triple therapy resulted in RR
of: 0.77 (95% CI: 0.65, 0.92; 23% difference; p = 0.005) [17];
0.85 (95% CI: 0.80, 0.90; 15% difference; p < 0.001) [25];
0.65 (95% CI: 0.49, 0.86; 35% difference; p = 0.002) [24] and
0.82 (95% CI: 0.58, 1.17; 18% difference; p = 0.2792) [26].
Langham et al. Respiratory Research          (2019) 20:242 Page 5 of 13
The patient-based NNT with triple therapy compared to
LABA/ICS was around 25. The event-based NNT ranged
from 6 (IMPACT) to 8 (TRILOGY). In the study that
assessed single-inhaler triple therapy with a LAMA (GLY/
FOR/BDP versus tiotropium [TIO]), triple therapy resulted
in a RR of 0.80 (95% CI: 0.69, 0.92; 20% difference; p =
0.0025), with a patient-based NNT of around 25 and an
event-based NNT of 9.
Prior exacerbation frequency subgroup
For the prior exacerbation frequency subgroup, triple
therapy demonstrated a higher reduction in the rate of
moderate and severe exacerbations in patients with a
history of more exacerbations than those who experi-
enced fewer exacerbations compared to LAMA/LABA
(IMPACT [21]), LABA/ICS (TRILOGY) and LAMA
(TRINITY). However, the converse was also found in
comparisons with LAMA/LABA (TRIBUTE) and LABA/
ICS (IMPACT [21]) where triple therapy demonstrated a
higher reduction in the rate of moderate and severe ex-
acerbations in patients who experienced fewer historical
exacerbations compared to those with a higher fre-
quency of historical exacerbations. A post-hoc analysis
of data from the FULFIL study showed that, compared
with LABA/ICS, triple therapy resulted in a significantly
higher reduction in moderate and severe exacerbation
rates in patients who had experienced ≥1 severe exacer-
bation, and 0/1 moderate exacerbations; patients who
experienced ≥2 moderate exacerbations also experienced
a rate reduction but the difference was not statistically
significant [20]. There were no data relating to prior ex-
acerbation frequency subgroups in the KRONOS study.
Eosinophil subgroup
For the eosinophil subgroup, in the TRINITY, TRIB-
UTE, IMPACT and KRONOS studies there was a higher
reduction in the rate of moderate and severe
exacerbations in patients with higher eosinophil counts
than those with lower counts for triple therapy compari-
sons with LAMA/LABA (TRIBUTE, IMPACT and
KRONOS) and LAMA (TRINITY). However, in the
TRILOGY study (triple therapy [GLY/FOR/BDP] versus
LABA/ICS), there was no association between blood eo-
sinophil concentration and the rate of moderate and se-
vere exacerbations. In the IMPACT study there was a
higher reduction in the rate of moderate and severe ex-
acerbations in patients with lower eosinophil counts
than those with higher counts for triple therapy com-
pared with LABA/ICS. In the KRONOS study (triple
therapy [GLY/FOR/B] versus LABA/ICS), there were
similar rates of moderate and severe exacerbations
across most eosinophil subgroups. There were no data
relating to eosinophil subgroups in the FULFIL study.
Smoking status subgroup
For the smoking status subgroup, there was a strong
trend for a higher reduction in the rate of moderate and
severe exacerbations in ex-smokers compared to
smokers for triple therapy comparisons with LAMA/
LABA in the largest study (IMPACT) and against
LABA/ICS in TRILOGY. For the triple therapy compari-
sons with LAMA/LABA in TRIBUTE and LAMA in
TRINITY, reduction in the rate of exacerbations was
greater for smokers. There were no data relating to
smoking status subgroups in the FULFIL or KRONOS
studies.
Secondary outcomes
Time to first exacerbation
In the TRINITY, TRILOGY and IMPACT studies the
time to first moderate or severe exacerbation was signifi-
cantly extended with triple therapy compared with
LAMA/LABA, LABA/ICS and LAMA (Fig. 4). In the
KRONOS study, the time to first moderate or severe
Fig. 2 Annual rate of moderate and severe exacerbations. COPD chronic obstructive pulmonary disease, FULFIL Lung FUnction and quality of LiFe
assessment in COPD with closed trIpLe therapy, ICS inhaled corticosteroids, IMPACT InforMing the PAthway of COPD Treatment, LABA long-acting
β2 agonist, LAMA long-acting muscarinic antagonist
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exacerbation was extended with triple therapy; the im-
provement was significant with LAMA/LABA (hazard
ratio [HR]: 0.59; p < 0.0001 [Cox regression] and p =
0.0001 [log rank]), but not with LABA/ICS (HR: 0.75;
p = 0.0635 [Cox regression] and p = 0.0281 [log rank]).
The TRIBUTE study showed a similar time to first mod-
erate or severe exacerbation with triple therapy and
LAMA/LABA (HR: 0.90; 95% CI: 0.76, 1.06; p = 0.22).
Fig. 3 Descriptive presentation of the annual rate of moderate and severe exacerbations for within-trial comparisons. B budesonide, BDP
beclomethasone, CI confidence interval, COPD chronic obstructive pulmonary disease, FF fluticasone furoate, FOR formoterol fumarate, FULFIL
Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy, GLY glycopyrronium bromide, ICS inhaled corticosteroids,
IMPACT InforMing the PAthway of COPD Treatment, IND indacaterol, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, NA
not available, NNT number needed to treat, TIO tiotropium, UMEC umeclidinium, VI vilanterol. #Calculated. ¶Estimated from graph. +A 24-week
study. Rate ratios, 95% CIs and NNT for annual rate of moderate and severe exacerbations between triple therapy and comparators, overall and
by subgroups for each within-trial comparison of triple therapy and LAMA/LABA, LABA/ICS and LAMA. Cross-trial comparisons are descriptive
only. NNT were only calculated for 52-week studies, ~ numbers used in calculation estimated from graph
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There were no data relating to time to first moderate or
severe exacerbation in the FULFIL study.
Lung function
In the three studies that assessed the single-inhaler triple
therapy GLY/FOR/BDP (TRINITY, TRILOGY and
TRIBUTE), triple therapy resulted in a significant change
from baseline in pre-dose FEV1 compared with LAMA
(61mL; 95% CI: 37, 86; p < 0.0001 [52-week data]) [16],
LABA/ICS (81 mL; 95% CI: 52, 109; p < 0.001 [26-week
data], 63 mL; 95% CI: 32, 94; p < 0.001 [52-week data])
[17] and LAMA/LABA (22mL overall; p < 0.05) [23]. In
terms of FEV1 change from baseline, patients were more
likely to respond (defined as change from baseline in
pre-dose FEV1 ≥ 100 mL) to triple therapy than to
LAMA (odds ratio [OR]: 1.61; 95% CI: 1.34, 1.93; p <
0.0001 [26-week data], 1.62; 95% CI: 1.35, 1.95; p <
0.0001 [52-week data]) [16], LABA/ICS (OR: 2.30; 95%
CI: 1.82, 2.91; p < 0.001 [26-week data], 2.06; 95% CI:
1.62, 2.62; p < 0.001 [52-week data]) [17] but not
LAMA/LABA (OR: 1.19; 95% CI: 0.91, 1.55; p = 0.198])
[23]. A further post-hoc analysis of the TRINITY study
considered different thresholds for FEV1 response. At
week 26, the proportion of responders (using a 50mL
threshold definition) was 48.0% for single-inhaler GLY/
FOR/BDP and 35.7% for TIO; using a 120 mL threshold
the proportions were 36.7% for single-inhaler GLY/FOR/
BDP and 25.3% for TIO [32].
In the two studies that assessed the single-inhaler
triple therapy UMEC/VI/FF (FULFIL and IMPACT),
triple therapy resulted in a significant change from base-
line in pre-dose FEV1 compared with LABA/ICS (FOR/
B, 171mL; 95% CI: 148, 194; p < 0.001 [24-week data],
179 mL; 95% CI: 131, 226; p < 0.001 [52-week data] [24];
VI/FF, 97 mL; 95% CI: 85, 109; p < 0.001 [52-week data])
[25] and LAMA/LABA (54 mL; 95% CI: 39, 69; p < 0.001
[52-week data]) [25]. In terms of FEV1 change from
baseline, patients were more likely to respond (defined
as change from baseline in trough FEV1 ≥ 100 mL) to
triple therapy than to LABA/ICS (FOR/B, OR: 4.03; 95%
CI: 3.27, 4.97; p < 0.001 [24-week data], 4.79; 95% CI:
3.02, 7.61; p < 0.001 [52-week data]) [24]. FEV1 response
was not reported in the IMPACT study.
In the study that assessed the single-inhaler triple ther-
apy GLY/FOR/B (KRONOS), triple therapy resulted in a
significant change from baseline in pre-dose FEV1 com-
pared with LAMA/LABA (22 mL; 95% CI: 4, 39; p =
0.0139), LABA/ICS (74 mL; 95% CI: 52, 95; p < 0.0001)
[26]. FEV1 response was not reported in the KRONOS
study.
Quality of life
Across all the studies quality of life was assessed using
the St. George’s Respiratory Questionnaire (SGRQ) [33].
In the three studies that assessed the single-inhaler triple
therapy GLY/FOR/BDP (TRINITY, TRILOGY and
TRIBUTE), triple therapy resulted in greater improve-
ment in SGRQ total score compared with TIO (at all
timepoints except week 26 [weeks 4 and 12: p < 0.001;
week 40: p < 0.01; week 52: p < 0.05]) [16], LABA/ICS
(at weeks 4, 12 and 52 [week 52 mean treatment differ-
ence: –1.69; 95% CI: − 3.20, − 0.17; p = 0.029]) [17] and
LAMA/LABA (week 4 and 12: p ≤ 0.001; week 26: p <
0.05; week 40 and 52: p < 0.01) [23]. In terms of SGRQ
response (defined as decrease from baseline in total
score ≥ 4 units), triple therapy was superior to TIO (OR:
1.32; 95% CI: 1.10, 1.57; p = 0.0024 [26-week data], 1.33;
95% CI: 1.11, 1.59; p = 0.0019 [52-week data]) [16] and
LABA/ICS (OR: 1.52; 95% CI: 1.21, 1.91; p < 0.001 [26-
week data], 1.33; 95% CI: 1.06, 1.66; p = 0.014 [52-week
Fig. 4 Time to first moderate or severe exacerbation. CI confidence interval, COPD chronic obstructive pulmonary disease, FULFIL Lung FUnction
and quality of LiFe assessment in COPD with closed trIpLe therapy, ICS inhaled corticosteroids, IMPACT InforMing the PAthway of COPD
Treatment, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, NR not reported, TIO tiotropium. Hazard ratios for time to first
moderate or severe exacerbation with triple therapy compared with comparators
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data]) [17], but not LAMA/LABA (OR: 1.22; 95% CI:
0.99, 1.51; p = 0.068 [52-week data]) [23].
In the two studies that assessed the single-inhaler
triple therapy UMEC/VI/FF (FULFIL and IMPACT),
triple therapy resulted in a greater improvement in
SGRQ total score compared with LABA/ICS (FOR/B, at
week 24 [difference: − 2.2 units; 95% CI: − 3.5, − 1.0; p <
0.001] [24]; VI/FF, at week 52 [difference: –1.8; 95% CI:
− 2.4, − 1.1; p < 0.001]) [25] and LAMA/LABA (at week
52 [difference: –1.8; 95% CI: − 2.6, − 1.0; p < 0.001]) [25].
In the IMPACT study, there were similar changes in
SGRQ total score for LAMA/LABA and LABA/ICS [25].
In terms of SGRQ response (defined as decrease from
baseline in total score ≥ 4 units), triple therapy was su-
perior to LABA/ICS (FOR/B, OR: 1.41; 95% CI: 1.16,
1.70; p < 0.001 [24-week data] [24]; VI/FF, OR: 1.41; 95%
CI: 1.29, 1.55; p < 0.001 [52-week data]) [25] and LAMA/
LABA (OR: 1.41; 95% CI: 1.26, 1.57; p < 0.001 [52-week
data]) [25].
In the study that assessed the single-inhaler triple ther-
apy GLY/FOR/B (KRONOS), triple therapy resulted in
nominally significant improvements in SGRQ total score
over 24 weeks compared with LAMA/LABA (difference:
–1.22; 95% CI: − 2.30, − 0.15; p = 0.0259), but not
LAMA/ICS (difference: –0.45; 95% CI: − 1.78, 0.87; p =
0.5036) [26]. In terms of SGRQ response (defined as
decrease from baseline in total score ≥ 4 units), triple
therapy was associated with nominally significant im-
provements compared with LAMA/LABA (OR: 1.28;
95% CI: 1.01, 1.61; p = 0.0395) but not LABA/ICS (OR:
1.30; 95% CI: 0.97, 1.72; p = 0.0746) [26].
Safety
Across all the studies, SAEs were comparable between
triple therapy and comparators. In the three studies that
assessed the triple therapy GLY/FOR/BDP (TRINITY,
TRILOGY and TRIBUTE), triple therapy was associated
with a similar percentage of patients who experienced
SAEs (13 [16]–15% [17, 23]) compared with TIO (15%)
[16], LABA/ICS (18%) [17] and LAMA/LABA (17%) [23].
In the two studies that assessed the triple therapy
UMEC/VI/FF (FULFIL and IMPACT), triple therapy
was associated with a similar percentage of patients who
experienced SAEs (5.4% [24] [24-week data], 10 [24]–
22% [25] [52-week data]) compared with LABA/ICS
(FOR/B, 5.7% [24-week data], 12.7% [52-week data] [24];
VI/FF, 21% [52-week data]) [25] and LAMA/LABA (23%
[52-week data]) [25].
In the study that assessed the single-inhaler triple ther-
apy GLY/FOR/B (KRONOS), triple therapy was associ-
ated with SAEs in 9% of patients compared with 11% for
LAMA/LABA and 7% for LABA/ICS [26].
In all studies, except FULFIL and IMPACT, pneumonia
was reported in 1 to 4% of patients, with similar incidences
in the treatment groups within each study. Pneumonia was
defined as an adverse event (AE) by the investigator in each
of these studies and additionally, in the KRONOS study,
was validated using supporting diagnostic and treatment
criteria.
In the FULFIL study, there was a higher rate of pneu-
monia (defined as an AE with supporting radiography)
for triple therapy compared with LABA/ICS up to 24
weeks (2.1% versus 0.8%); the rates were similar between
the two groups at 52 weeks (1.9% versus 1.8%). In the
IMPACT study there was a higher incidence of pneumo-
nia (defined as an AE of special interest with supporting
radiography) with the triple therapy (UMEC/VI/FF; 8%)
and LABA/ICS (7%), than with LAMA/LABA (5%). The
rate of pneumonia per 1000 patient-years was 95.8 for
triple therapy, 61.2 for LAMA/LABA and 96.6 for
LABA/ICS. For pneumonia defined as a SAE with sup-
porting radiography, the rate per 1000 patient-years was
53.3 for triple therapy, 32.4 for LAMA/LABA and 47.7
for LABA/ICS. The risk of pneumonia was significantly
higher with triple therapy than with LAMA/LABA, as
assessed in a time-to-first-event analysis (HR: 1.53; 95%
CI: 1.22, 1.92; p < 0.001) [25].
In the TRINITY, TRILOGY, TRIBUTE and FULFIL
studies, mortality was reported to be similar in each arm
and not related to study medication. A pooled analysis
of the time to death in the TRINITY, TRILOGY and
TRIBUTE studies did not show a significant reduction
in the risk of developing a fatal event compared with
ICS-free treatments (LAMA and LAMA/LABA, HR:
0.72; 95% CI: 0.49, 1.06; p = 0.096) [22]. In the IMPACT
study, for the prespecified endpoint, there was a statisti-
cally significant reduction in the risk of time to on- and
off-treatment all-cause mortality for triple therapy com-
pared to LAMA/LABA (HR: 0.71; 95% CI: 0.51, 0.99; un-
adjusted p = 0.043) but not LABA/ICS. Similar results
were seen when off-treatment information was included.
The percentage of on- and off-treatment deaths in each
arm were 2.14% with UMEC/VI/FF, 2.35% with VI/FF
and 2.90% with UMEC/VI [25]. In the KRONOS study,
there were two deaths in the LAMA/LABA group that
were considered to be related to study treatment [26].
Discussion
Overall, this systematic review demonstrates, that in
patients with predominantly severe lung function im-
pairment and a history of frequent exacerbations, single-
inhaler triple therapy results in a reduction in moderate
and severe exacerbations. Over 1 year, triple therapy
reduced the frequency of moderate and severe exacerba-
tions by 15 to 52% compared to LAMA/LABA, and 15
to 35% compared to LABA/ICS. The patient-based NNT
ranged from around 25 to 50 (preventing one patient
from having an event) and the event-based NNT ranged
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from around 3 to 11 (preventing one event). The abso-
lute benefit appears to be greater in phenotypic sub-
groups with higher eosinophil counts or higher historical
frequency of exacerbations and to some extent, ex-
smokers. The reductions in exacerbations come at the
expense of a significant increase in pneumonia for some
regimens, including pneumonia as a SAE.
Single-inhaler triple therapy showed some improve-
ments in lung function and health-related quality of life
over comparators. However, for the responder analysis
(where threshold definitions reflected minimal clinically-
important differences), comparisons against LAMA/
LABA were not significant, indicating the differences
were small and potentially not clinically relevant.
Previous reviews assessing triple therapy, in general,
have demonstrated a reduction in exacerbations and an
improvement in lung function and health-related quality
of life but with an increased risk of pneumonia [3–7].
Our findings are consistent with a previously published
review of multiple and single inhaler triple therapies,
which included three of the six single inhaler clinical tri-
als included in the present study. Although results for
single inhalers were not reported separately, the results
indicate that the benefit of triple therapy in reducing the
risk of exacerbation is greater in patients with higher eo-
sinophil counts [7]. Overall, the magnitude of clinical
benefit for single-inhaler triple therapy, particularly
across multiple subgroups, has not been well docu-
mented, which was the focus of our study. This study is
the first to systematically review and descriptively assess
the relative and absolute efficacy and safety of all six
single-inhaler triple therapy studies compared to dual
and monotherapy and explore differences in efficacy be-
tween phenotypic subgroups.
We also critically assessed the evidence base for single-
inhaler triple therapy, which is currently not well docu-
mented. There were important differences in study designs
and populations that would give rise to significant hetero-
geneity if class-level or drug-level meta-analyses of single-
inhaler triple therapies were conducted, meaning results of
such studies would need to be treated with caution. First,
prior triple therapy was allowed in some trials and not
others. The UMEC/VI/FF studies (FULFIL and IMPACT)
allowed patients on triple therapy at the time of randomisa-
tion to enter the trial. In the IMPACT study 35% of pa-
tients in both the LAMA/LABA and LABA/ICS arms
experienced ICS withdrawal at the time of randomisation.
Second, some trials allowed abrupt withdrawal of ICS prior
to study start. In the IMPACT study, more than 70% of pa-
tients randomised to LAMA/LABA were receiving ICS at
randomisation. In the TRIBUTE study, all patients were
switched to LAMA/LABA at the start of the 2-week run-in
period. This included 65% of patients who were taking
LABA/ICS or LAMA/ICS for at least 2months before
study entry. No subgroup analyses were done according to
previous treatment. Third, there were differences in the se-
verity of COPD between the trials, particularly in relation
to prior exacerbation history, with one study (KRONOS)
including patients without a prior history of exacerbations,
a group not recommended for treatment with triple therapy
according to the recent GOLD update [2]. Fourth, different
regimens were used, which may impact the risks and bene-
fits observed. Finally, the IMPACT trial also allowed pa-
tients with a prior history of asthma. As these data were
not recorded, however, it is difficult to know whether this
influenced results. All of these factors could lead to exag-
geration of the benefits of ICS. Some studies have shown
that abrupt withdrawal of ICS may lead to an increase in
exacerbations in some patients [34–36], unlike a managed
stepwise withdrawal of ICS [37]. Class-level meta-analyses
including free-combination triple therapies and limited data
on single-inhaler triple therapies have found statistical and
clinical heterogeneity to be a significant concern [6, 7].
The IMPACT study reported a benefit in the risk of
time to all-cause mortality for triple therapy compared to
LAMA/LABA. As none of the single-inhaler triple therapy
studies were powered for a mortality outcome, these re-
sults should be treated with caution and investigated fur-
ther. Two prospective, adequately-powered, large-scale
studies with a primary outcome of mortality failed to dem-
onstrate a significant reduction in mortality associated
with the use of ICS-containing regimens [38, 39].
Our review attempted to determine whether the bene-
fits associated with triple therapy in COPD were clinic-
ally meaningful by assessing and comparing relative and
absolute improvements in outcomes as well as the NNT.
These latter results are of interest as they translate the
results of randomised trials into a value that clinicians
can use in decision making. Focusing on the 12-month
trials, we found relatively high NNTs for therapy at 12
months (> 20) in terms of reducing the numbers of indi-
viduals experiencing exacerbations but lower NNTs (3
to 11) for reducing one exacerbation per patient per
year. The discrepancy between these two numbers sug-
gests that the impact of triple therapy is not necessarily
to increase the number of patients staying exacerbation
free, but that the largest effect is in reducing the number
of events in patients having multiple events. Such pa-
tients are most likely the high-risk individuals with a
higher rate of baseline exacerbations and blood eosino-
philia as suggested by the subgroup data. The evidence
therefore supports a targeted approach to triple therapy
use in those patients at highest risk of exacerbation with
higher levels of blood eosinophilia. It also implies that
the vast majority of patients with a lower baseline risk of
exacerbation and lower blood eosinophilia may experi-
ence less benefit from ICS, as reflected in the GOLD up-
date [2]. The increased risk of ICS, particularly in
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relation to pneumonia, is well documented [40], and
likely to vary by treatment-related factors (e.g. regimen
and dose) and study design-related factors (e.g. patient
characteristics and definitions used) [41]. In the present
study, the pneumonia risk for single-inhaler triple ther-
apy ranged from no reported increase to a significant in-
crease. Taking the study demonstrating the highest risk
and translating it into an event-based number needed to
harm (NNH) to induce pneumonia in at least one pa-
tient over one year, gives an NNH of 33.
The next step is to more clearly define patient groups
where ICS are of benefit. This review demonstrated that
patients with higher eosinophil counts, higher prior ex-
acerbation frequency and ex-smokers, in general, bene-
fited more from single-inhaler triple therapy; however,
results for all three phenotypes were mixed. This may
have resulted, in part, from the thresholds that were used
in these studies. The GOLD 2019 document suggests that
patients with blood eosinophil counts < 100 and ≥ 300
cells/μL point to subgroups with lower and higher likeli-
hood of treatment benefit with ICS [2]. There is a need to
validate and refine this threshold and identify other
patient characteristics that can support the treatment
decision to step up to triple therapy.
The limitations of our systematic review largely reflect
the shortcomings of the included studies. First, there was
limited information reported in the studies on subgroups
and information needed to calculate patient-based NNTs
therefore a number of the results were either calculated
based on available data or estimated from forest plots or
Kaplan–Meier curves. Second, interpretation of subgroup
data needs to be treated with caution. Many subgroup
analyses were not prespecified in the original study and
studies were not powered to demonstrate an interaction
effect. In addition, although the inclusion criteria for this
review were carefully chosen to answer the research ques-
tion, broadening the criteria, for example by including all
types of randomised controlled trials of any duration, may
have had an impact on the interpretation of the results.
However, a review with broader inclusion criteria, pre-
sented similar overall findings [7].
Overall the evidence from these studies support the
GOLD 2019 treatment strategy in that triple therapy
should be reserved for a select group of patients with
COPD with frequent exacerbations and higher eosino-
phil counts thereby maximising benefit and minimising
risk [2]. Future research on specific patient phenotype
thresholds that can support treatment and funding
decisions is now required from well-designed, robust,
clinical trials.
Conclusions
Our analysis of single-inhaler triple therapy trials sug-
gests that in the patient populations included in these
studies, 25–50 patients would need to be treated with
single-inhaler triple therapy to prevent one patient from
having a moderate or severe exacerbation over one year
compared with dual therapy, with an NNH for the pneu-
monia AE of around 33 and upwards. This emphasises
that we must weigh benefits and risks of ICS in individ-
ual patients. Our analyses suggest benefit appears to be
greatest in patients with higher eosinophil counts,
greater historical frequency of exacerbations, and ex-
smokers. This must be balanced against the increased
risk for AEs including pneumonia.
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